Main navigation About Tolmar Science & Innovation Treatments Responsibility Careers News Contact Press Tolmar in the News Tolmar is making news in our therapeutic areas and beyond. Read our clippings to learn more about our scientific and clinical advances as well as how we work to make a difference in the community. November 15, 2021 Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE® October 08, 2021 Tolmar Establishes Tolmar Canada to Sell, Market and Distribute ELIGARD® in Canada May 12, 2021 Centers for Medicare and Medicaid Services (CMS) Issues Permanent J-Code for Tolmar's FENSOLVI® Effective July 1, 2021 February 19, 2021 Tolmar Launches "Little a Little Longer" Campaign: A Caregiver's Guide to Central Precocious Puberty November 24, 2020 Tolmar Publishes FENSOLVI® (leuprolide acetate) for Injectable Suspension Safety and Efficacy Data in Journal of Clinical Endocrinology and Metabolism August 18, 2020 Tolmar Affirms Supply of FENSOLVI® (leuprolide acetate) for Pediatric Patients with Central Precocious Puberty August 10, 2020 Tolmar Affirms Full Supply of Eligard® (Leuprolide Acetate) for Injectable Suspension for the Palliative Management of Advanced Prostate Cancer May 04, 2020 FDA Approves FENSOLVI® (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty June 07, 2019 ELIGARD (leuprolide acetate) for Injectable Suspension Continues Growth Momentum With Favorable Formulary Positions - Placement with EnvisionRx Fuels Market-Leading Growth November 07, 2018 Tolmar Pharmaceuticals Sponsors 2018 ZERO – The End of Prostate Cancer Endurance Team at the Bank of America Chicago Marathon Pagination Next page ›› Tolmar press releases are archived on this site for historical purposes only. Information contained in the releases is accurate at the time of publication. Specific information included in these releases may change over time, and may or may not be accurate after the date on the release. Tolmar has no intention and specifically disclaims any duty to update the information in these historical press releases. Tolmar Pharmacueticals, Inc. Footer menu Contact Drug Distribution Accreditation – Learn More Media Privacy Policy Site Map Terms & Conditions ©2018-2020 Tolmar Pharmaceuticals, Inc. All rights reserved. TOLMAR, ELIGARD, FENSOLVI and ATRIGEL are trademarks of the TOLMAR group. Third party trademarks, product names, and copyrights belong to their respective owners. Back to Top